Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

Author(s):

Heather A. Wakelee, MD, FASCO,Jacob Sands, MD

Panelists discuss the situations in which other first-line therapies, such as cabozantinib or PD-L1–positive chemotherapy options, might be considered for RET fusion–positive non–small cell lung cancer (NSCLC), and compare the role of chemotherapy and immunotherapy to that of RET inhibitors in this setting.

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP: 2.Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP: 3.Testing Methodologies and Standards in Metastatic NSCLC

EP: 4.Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP: 5.Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP: 6.Initial Approach to Management of RET-Positive NSCLC

EP: 7.Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP: 8.Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

Now Viewing

EP: 9.Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

EP: 10.Managing RET Inhibitor Treatment-Related Adverse Events

Dr Sands to Dr Wakelee: In what situations do you consider other first-line therapies (eg, cabozantinib, PD-L1–positive chemotherapy options)?
- What is the role of chemotherapy and/or immunotherapy currently in RET fusion–positive NSCLC? How does this compare to RET inhibitors?